OBJECTIVES: Nowadays breast cancer represents a great economic burden to public healthcare sector in Mexico. This economic burden is due by a lack of prevention campaigns and late diagnosis. The analysis aims to estimate the economic impact of standard treatment in Mexico for an optimistic scenario of 80% of all breast cancer population at early stages compared to the actual distribution (55%) of patients along the stages in Mexican setting.  METHODS: A hypothetical patient cohort of 8765 was evaluated; this estimation was obtained from breast cancer 2011 prevalence in Mexican population. The analysis was developed in order to estimate average cost from the optimistic (base-case) versus actual scenario through public healthcare perspective. Distribution of population in the actual case scenario was 16%, 39%, 30% and 14% at each stage, I-IV respectively. Direct medical costs were extracted from a published source where through a micro-costing technique the cost at each stage was obtained. Costs are expressed in 2014 USD ($1USD=$13MXN).  It is assumed that the economical difference between both scenarios will be used for prevention campaigns.   RESULTS: The total cost of treatment for all patients on the actual scenario was $124,261,716 compared to $103,549,361 that was the cost calculated at the base-case scenario. Economic impact of optimistic scenario is 17% less than total cost of treatment at the current scenario. This difference, which represents $20,712,355, could be reallocated to diagnose 32,689 more patients at early stages. A sensitivity analysis with a best-case scenario was developed considering 100% of the patients diagnosed during the first two stages where economic benefits were 314% higher than base-case scenario.  CONCLUSIONS: This analysis suggests that if more public policies focused on breast cancer prevention were implemented, then it may lead to a more optimal reallocation of resources since direct medical costs increase at late stages.